Cardiex June 2024 Quarter Update

Cardiex Limited (ASX:CDX) is pleased to present its June 2024 quarter update.

Highlights:

• Robust Q4 and record FY24 financial results.
• Expanded product capabilities to drive continued revenue growth with strong internal projections for FY25 and beyond. ● Initial CONNEQT Pulse units have arrived in the USA and Australia and are being distributed to strategic healthcare partners for pilot programs, including extensive user testing and evaluation.
• Pre-launch activities for Pulse have exceeded expectations leading to an increase in the first full production run from 3,000 to 8,000 units (Q1 FY25).
• Multiple new regulatory clearances being sought in new geographic markets.
• Targeted marketing initiatives for the Pulse are accelerating to build awareness and drive leads through key industry events, online marketing, and other digital and social channels.
• Strengthened financial position with funding commitments from C2 Ventures.
• Investor webinar details and closing CEO comments.

Dear Fellow Shareholders,

On behalf of the Company I’m pleased to present our final Quarterly Update for FY 2024. As we approach a pivotal moment in our journey, I’m thrilled to highlight our recent achievements and the exciting developments on the horizon. Our dedicated efforts across various sectors have led to impressive financial results and a growing interest in our innovative products. With a strong foundation in place, including significant advancements in our ATCOR division and successful product launches, we are well placed for continued success.

In the lead-up to the launch of the CONNEQT Pulse, we are now preparing to shift our focus towards a more targeted and strategic marketing approach. This will include leveraging a diverse array of industry, social, and digital channels to amplify our reach and drive both awareness and sales. With new partnerships, expanded product capabilities, and continuing strategic initiatives, we are confidently moving forward to meet the increasing demand and deliver transformative solutions to our market.

Click here for the full ASX Release

This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.